Preventive screening measures hit the mark in type 2 diabetes

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.475, 2005-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Economics of Screening and Treatment in Type 2 Diabetes Mellitus

By Raikou M.   McGuire A.  

PharmacoEconomics, Vol. 21, Iss. 8, 2003-01 ,pp. : 543-564

Adis International

Access to resources Recommend Favorite

Screening for type 2 diabetes cost effective

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 601, 2010-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Cyclophilin-A: a potential screening marker for vascular disease in type-2 diabetes

By Ramachandran Surya   Kartha C.C.  

Canadian Journal of Physiology and Pharmacology, Vol. 90, Iss. 8, 2012-08 ,pp. : 1005-1015

NRC Research Press

Access to resources Recommend Favorite

The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery

By  

Medicinal Chemistry, Vol. 13, Iss. 8, 2017-11 ,pp. : 706-720

Bentham Science Publishers

Access to resources Recommend Favorite

Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus: A Systematic Literature Review

By Vijgen Sylvia M.C.   Hoogendoorn Mirjam   Baan Caroline A.   G. Ardine de Wit   Limburg Wien   Feenstra Talitha L.  

PharmacoEconomics, Vol. 24, Iss. 5, 2006-01 ,pp. : 425-441

Adis International

Access to resources Recommend Favorite